NSWRC(SH:600165)2018-10-26 16:00Financial Performance - Operating revenue for the first nine months was CNY 480,876,935.17, down 57.93% year-on-year [6]. - Net profit attributable to shareholders was CNY 329,264.52, compared to a loss of CNY 785,281.83 in the same period last year [6]. - Basic earnings per share were CNY 0.0005, compared to a loss of CNY 0.001 in the same period last year [6]. - Total operating revenue for Q3 was 145,489,688.33, a decrease from 578,935,612.98 in the same period last year [35]. - Net profit for Q3 reached 6,096,628.79, compared to 13,072,065.27 in the previous year [36]. - The company reported a total of 3,337,066.44 in net profit for the period, a recovery from a loss of -7,929,258.26 in the previous year [39]. - The total comprehensive income for the third quarter was CNY 3,337,066.44, a decrease of CNY 7,929,258.26 compared to the previous year [40]. - Basic earnings per share (EPS) for the third quarter was CNY 0.0049, down from CNY 0.0125 year-over-year, representing a decline of 60.8% [40]. Cash Flow - Net cash flow from operating activities was negative CNY 166,021,592.18, a decrease of 133.86% compared to the previous year [6]. - Cash inflow from operating activities totaled CNY 577,815,148.74, down 60.6% from CNY 1,465,572,891.46 year-over-year [42]. - Cash outflow from operating activities was CNY 743,836,740.92, a decrease of 23.8% compared to CNY 975,258,343.09 in the previous year [42]. - Cash flow from investment activities generated a net inflow of CNY 275,792,988.07, down from CNY 510,847,290.99 year-over-year [43]. - Cash flow from financing activities resulted in a net outflow of CNY 21,109,588.66, compared to a net outflow of CNY 1,081,134,700.35 in the previous year [43]. - The ending cash and cash equivalents balance was CNY 133,295,895.28, an increase from CNY 63,006,172.03 year-over-year [43]. - The company received CNY 300,000,000.00 from investment recoveries, significantly up from CNY 60,000,000.00 in the previous year [42]. - The company reported a decrease in cash inflow from sales of goods and services, totaling CNY 404,772,862.52, down from CNY 1,339,538,824.00 year-over-year [42]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,268,033,231.62, a decrease of 1.35% compared to the end of the previous year [6]. - Current liabilities totaled ¥1,240,448,518.58, down from ¥1,278,130,536.73 [28]. - Non-current liabilities reached ¥3,084,791.70, compared to ¥697,070.56 at the beginning of the year [28]. - The total liabilities were ¥1,243,533,310.28, a decrease from ¥1,278,827,607.29 [28]. - Owner's equity totaled ¥1,024,499,921.34, up from ¥1,020,216,356.55 [28]. - Total current assets amounted to ¥1,168,078,475.87, slightly up from ¥1,153,578,485.00 [31]. - Long-term investments increased to ¥1,045,427,929.02 from ¥1,040,191,524.85 [31]. Shareholder Information - The total number of shareholders at the end of the reporting period was 52,832 [9]. - The largest shareholder, Shanghai Zhongneng Enterprise Development (Group) Co., Ltd., held 200,000,000 shares, accounting for 29.20% of total shares [9]. Operational Challenges - The company has faced challenges in accurately predicting the future profitability of its assets due to uncertainties in government subsidies for the new energy vehicle sector [21]. - The company has decided to terminate its major asset restructuring plan due to uncertainties regarding the evaluation methods and transaction prices with counterparties [21]. - The company is involved in ongoing litigation and arbitration related to a loan dispute amounting to ¥80 million [16]. - The company has initiated legal proceedings against Xu Xiaochun for failure to fulfill performance compensation obligations related to Boya Stem Cell [22]. - The company’s internal control audit report received a negative opinion due to significant deficiencies in the management of its subsidiaries [18]. Revenue and Expenses - Operating costs decreased by 53.22% to ¥444,710,733.73 from ¥950,617,625.08 [14]. - Sales expenses decreased by 88.56% to ¥10,547,790.71 from ¥92,176,608.09 [14]. - Management expenses decreased by 57.22% to ¥20,592,293.46 from ¥48,130,974.92 [14]. - Research and development expenses for Q3 were 115,603.16, down from 317,801.62 in the same period last year [35]. - Non-operating income and expenses totaled CNY -31,829.20, indicating a negative impact on overall profitability [8].